Spyre CEO sells 15,000 shares under 10b5-1 plan

Spyre Therapeutics, Inc. reported that Chief Executive Officer and director Cameron Turtle sold a total of 15,000 shares of common stock in three open-market transactions on June 1, 2026 at prices ranging from the high-$60s to low-$70s per share.

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. reported that Chief Executive Officer and director Cameron Turtle sold a total of 15,000 shares of common stock in three open-market transactions on June 1, 2026 at prices ranging from the high-$60s to low-$70s per share. These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025, indicating they were pre-arranged. Following the transactions, the filing shows Turtle directly holding 597,540 shares of common stock, which includes 87,138 shares that vest in monthly installments through November 2026, subject to continued service.

Insider Trade Summary 10b5-1

Net Seller: 15,000 shares

Net Sell 3 txns

Insider Turtle Cameron

Role Chief Executive Officer

Sold 15,000 shs ($1.06M)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,557	$69.40	$247K
Sale	Common Stock	8,149	$70.50	$575K
Sale	Common Stock	3,294	$71.38	$235K

Holdings After Transaction: Common Stock — 597,540 shares (Direct)

Footnotes (5)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
2. F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.96 to $69.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. Includes 87,138 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
4. F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.96 to $70.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
5. F5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.97 to $71.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Total shares sold: 15,000 shares Sale price tranche 1: $69.40 per share Sale price tranche 2: $70.50 per share +3 more

6 metrics

Total shares sold 15,000 shares Open-market sales on June 1, 2026

Sale price tranche 1 $69.40 per share Weighted average for 3,557 shares sold

Sale price tranche 2 $70.50 per share Weighted average for 8,149 shares sold

Sale price tranche 3 $71.38 per share Weighted average for 3,294 shares sold

Shares held after transactions 597,540 shares Direct common stock holdings following reported sales

Unvested shares 87,138 shares Vest monthly through November 2026, subject to service

Key Terms

Rule 10b5-1 trading plan, weighted average price, vesting, monthly installments

4 terms

Rule 10b5-1 trading plan financial

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported above is a weighted average price. The shares were sold in multiple transactions..."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

vesting financial

"Includes 87,138 shares of common stock that vest in monthly installments through November 2026..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

monthly installments financial

"shares of common stock that vest in monthly installments through November 2026, subject to the continuing service..."

Monthly installments are regular, fixed payments made each month to gradually pay off a larger amount, such as a loan or purchase. Think of it like paying for a big item in small, manageable parts instead of all at once. For investors, understanding installment payments helps gauge how debts are structured and how they might affect financial stability or cash flow over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Spyre Therapeutics (SYRE) disclose for Cameron Turtle?

Spyre Therapeutics disclosed that CEO and director Cameron Turtle sold 15,000 shares of common stock in three open-market transactions. The sales occurred on June 1, 2026 at prices in the high-$60s to low-$70s per share, according to the Form 4 filing.

At what prices did the SYRE CEO sell shares on June 1, 2026?

The CEO’s sales used weighted average prices of $69.40, $70.50, and $71.38 per share. Footnotes state individual trades occurred in ranges from $68.96 up to $71.93 per share, with detailed trade breakdowns available upon request from the issuer or the SEC.

How many Spyre Therapeutics shares does Cameron Turtle hold after the Form 4 transactions?

After the reported sales, the filing shows Cameron Turtle directly holding 597,540 shares of Spyre Therapeutics common stock. This total includes 87,138 shares that are scheduled to vest in monthly installments through November 2026, conditioned on his continued service.

Were the SYRE CEO’s June 1, 2026 share sales under a Rule 10b5-1 plan?

Yes. A footnote explains the June 1, 2026 transactions were executed under a Rule 10b5-1 trading plan adopted on June 20, 2025. Such plans pre-schedule trades, indicating the timing was determined in advance rather than as a discretionary market-timing decision.

Are any of Cameron Turtle’s SYRE shares subject to vesting conditions?

Yes. The Form 4 notes that 87,138 of Cameron Turtle’s common shares vest in monthly installments through November 2026. Each vesting installment is subject to his continued service with Spyre Therapeutics on the applicable vesting dates, reflecting ongoing equity compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 09:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Turtle Cameron

(Last) (First) (Middle)

221 CRESCENT STREET, BUILDING 23,

SUITE 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		S(1)		3,557	D	$69.4(2)	608,983(3)	D
Common Stock	06/01/2026		S(1)		8,149	D	$70.5(4)	600,834(3)	D
Common Stock	06/01/2026		S(1)		3,294	D	$71.38(5)	597,540(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.96 to $69.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. Includes 87,138 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.

4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.96 to $70.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.97 to $71.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)